Sofinnova Investments overview
Stories about Sofinnova Investments
Sofinnova Investments contact information
Offices
3000 Sand Hill Road, Building 3, Suite 150, Menlo Park, 94025, United StatesContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Ms. Nathalie Auber | Job titleChief Financial Officer and Partner | LocationMenlo Park, United States | Email  ----- |
| Key ContactMs. Tiffany Davis | Job titleDirector of Investor Relations and Marketing, Private Equity | LocationMenlo Park, United States | Email ---------- |
| Mr. Hooman Shahlavi | Job titlePartner and Chief Legal Officer | LocationMenlo Park, United States | Email ----- |
| Dr. James Healy | Job titleManaging Partner | LocationMenlo Park, United States | Email -------- |
Sofinnova Investments funds managed
Funds in market: 1
| Fund | Fund size | Open date | Strategy |
|---|---|---|---|
Fund size ------ | Open dateDec 2024 | Strategy ------- | |
Closed funds: 11
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size ------ | Close dateSep 2023 | Strategy ---------- | |
Fund size ---------- | Close dateOct 2016 | Strategy ---------- | |
Fund size ----------- | Close dateJul 2014 | Strategy ---------- | |
Stories that mention Sofinnova Investments
Side Letter: PE's $160trn grail
Private equity's biggest hitters take aim at the $160 trillion retail market, according to panellists at IPEM Paris. Plus: PE and VC deal values hit a four-year low; and Australian private investments are outperforming publicly traded instruments. Here's today's brief, for our valued subscribers only.
Biotech bang for buck(3)
Biotechnology and life sciences companies require significant investment capital, and multi-million dollar investment rounds have recently grabbed headlines. But depending on the technologies being developed, the underlying research can be more or less expensive, providing many types of opportunities for investors. David Rapp spoke with leading biotech investors to learn more.
Biotech bang for buck(2)
Biotechnology and life sciences companies require significant investment capital, and multi-million dollar investment rounds have recently grabbed headlines. But depending on the technologies being developed, the underlying research can be more or less expensive, providing many types of opportunities for investors. David Rapp spoke with leading biotech investors to learn more.
Biotech bang for buck
Biotechnology and life sciences companies require significant investment capital, and multi-million dollar investment rounds have recently grabbed headlines. But depending on the technologies being developed, the underlying research can be more or less expensive, providing many types of opportunities for investors. David Rapp spoke with leading biotech investors to learn more.
QUALCOMM invests in Streamezzo
QUALCOMM Ventures has invested in French mobile software company Streamezzo, as venture capital firms attempt to find alternative ways of making profits from the mobile industry.
Deal round-up 10/01/03
Benchmark backs BridgCo second round; AXA leads E10m mechanical systems round; Sofinnova invests in digital storage business; 3i backs Vanguard Healthcare round;Nordic Biotech leads Biotica funding
Deal round up 05/11/02
DrKC increases Euromedic investment; Sofinnova invests in US biopharma round; ICC backs 2PM Technologies second round
Index Ventures leads E34m financing round for Cellzome
The biopharmaceutical company will use the funding to boost infrastructure, programmes and recruit staff.